Research location
Fredericksburg
Texas, United States
Advertisement
Research activity in Fredericksburg
Texas, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 17 trials and 17 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Fredericksburg
17 linked trials · page 1 of 1Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung CancerNCT07226999 · 2025-12-09 · 1 site observation
RECRUITING
MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNPNCT06361108 · 2024-05-16 · 1 site observation
RECRUITING
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.NCT06072612 · 2023-12-05 · 1 site observation
RECRUITING
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7NCT04613596 · 2020-12-02 · 1 site observation
RECRUITING
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · 2022-10-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast CancerNCT00938652 · 2009-07-01 · 1 site observation
COMPLETED
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast CancerNCT00887536 · 2009-05-01 · 1 site observation
COMPLETED
Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)NCT00450970 · 2007-02-01 · 1 site observation
TERMINATED
Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast CancerNCT00394251 · 2006-08-01 · 1 site observation
COMPLETED
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast CancerNCT00248170 · 2005-12-01 · 1 site observation
COMPLETED
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast CancerNCT00320385 · 2005-11-01 · 1 site observation
COMPLETED
PhII ICb With/Without Erbitux in MBC PtsNCT00248287 · 2005-07-28 · 1 site observation
ACTIVE_NOT_RECRUITING
To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and OlderNCT00082095 · 2004-04-01 · 1 site observation
TERMINATED
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)NCT00087802 · 2004-03-01 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer PatientsNCT00080197 · 2004-02-01 · 1 site observation
COMPLETED
Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy RegimenNCT00069745 · 2003-09-01 · 1 site observation
COMPLETED
Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By ExemestaneNCT00036270 · 2001-08-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.